Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Fleshner

Showing results (161-170 of 266) with videos related to

Pageof 27
Sort By:
Contemporary Clinical Trials|June 19, 2007
Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trialNeil Fleshner, Leonard G Gomella, Michael S Cookson, et al.
Biopreservation and Biobanking|October 25, 2023
Biospecimen Qualification in a Clinical Biobank of Urological DiseasesOlga Kofanova, Sangita Paul, Achilleas Pexaras, et al.
The Journal of Urology|November 28, 2017
Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative EffectNathan Perlis, Thamir Al-Kasab, Ardalan Ahmad, et al.
BJU International|December 22, 2004
Variation in patterns of practice in diagnosing screen-detected prostate cancerRobert K Nam, Ants Toi, John Trachtenberg, et al.
Urologic Oncology|May 10, 2022
Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomesYazan Qaoud, Jaime O Herrera-Caceres, Roman Bass, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 19, 2021
Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic diseaseAdam Bobrowski, Ur Metser, Antonio Finelli, et al.
Urology|February 16, 2021
A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or EnzalutamideDixon T S Woon, Antonio Finelli, Douglas C Cheung, et al.
JAMA Network Open|August 27, 2024
5-α Reductase Inhibitors and Prostate Cancer MortalityRobert J Hamilton, Julian Chavarriaga, Najia Khurram, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
North American study and meta-analysis evaluating performance of Bladder EpiCheck<sup>®</sup>, a FDA cleared test, in non-muscle invasive bladder cancer recurrenceNeil Fleshner, Herbert Barton Grossman, Ryan Berglund, et al.
Cancer|April 2, 2021
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancerShabbir M H Alibhai, Henriette Breunis, Aaron R Hansen, et al.
Pageof 27

Showing results (161-170 of 266) with videos related to

Sort By:
Pageof 27
Contemporary Clinical Trials|June 19, 2007
Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trialNeil Fleshner, Leonard G Gomella, Michael S Cookson, et al.
Biopreservation and Biobanking|October 25, 2023
Biospecimen Qualification in a Clinical Biobank of Urological DiseasesOlga Kofanova, Sangita Paul, Achilleas Pexaras, et al.
The Journal of Urology|November 28, 2017
Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative EffectNathan Perlis, Thamir Al-Kasab, Ardalan Ahmad, et al.
BJU International|December 22, 2004
Variation in patterns of practice in diagnosing screen-detected prostate cancerRobert K Nam, Ants Toi, John Trachtenberg, et al.
Urologic Oncology|May 10, 2022
Salvage partial gland ablation for recurrent prostate cancer following primary partial gland ablation: Functional and oncological outcomesYazan Qaoud, Jaime O Herrera-Caceres, Roman Bass, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 19, 2021
Salvage lymph node dissection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-identified oligometastatic diseaseAdam Bobrowski, Ur Metser, Antonio Finelli, et al.
Urology|February 16, 2021
A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or EnzalutamideDixon T S Woon, Antonio Finelli, Douglas C Cheung, et al.
JAMA Network Open|August 27, 2024
5-α Reductase Inhibitors and Prostate Cancer MortalityRobert J Hamilton, Julian Chavarriaga, Najia Khurram, et al.
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
North American study and meta-analysis evaluating performance of Bladder EpiCheck<sup>®</sup>, a FDA cleared test, in non-muscle invasive bladder cancer recurrenceNeil Fleshner, Herbert Barton Grossman, Ryan Berglund, et al.
Cancer|April 2, 2021
Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancerShabbir M H Alibhai, Henriette Breunis, Aaron R Hansen, et al.
Pageof 27